Concepta PLC Corporate Update (7958O)
23 August 2017 - 9:00PM
UK Regulatory
TIDMCPT
RNS Number : 7958O
Concepta PLC
23 August 2017
Dissemination of a Regulatory Announcement that contains inside
information according to REGULATION (EU) No 596/2014 (MAR)
23 August 2017
Concepta plc
("Concepta" or the "Company")
CORPORATE UPDATE
Concepta makes first shipment of myLotus fertility product to
China
Founding member of Company appointed Head of China
Operations
Concepta plc (AIM: CPT) the pioneering UK healthcare company and
developer of a proprietary platform and suite of products targeted
at the personalised mobile health market with a primary focus on
women's fertility and specifically unexplained infertility, is
pleased to provide a positive update regarding its marketing and
sales drive into China of its myLotus fertility product.
Following the receipt of its first sales order, totalling
GBP225,000, for its myLotus fertility product from its partner in
China, HuanZhong Biotech Co.Ltd (see announcement 13 June 2017),
the Company has made its first shipment of products to China. As
part of this first shipment, the Company scaled up production of
its test strips at its UK manufacturing site in Sharnbrook,
Bedfordshire, allowing it to shorten its lead-time for shipment by
two weeks. The Company expects to make further regular shipments to
fulfil this order in the coming weeks.
The Company is also pleased to announce that it has appointed
Zhang Zhi Gang, as Head of China Operations. Zhang was one of the
founders of Concepta Diagnostics Limited and led the way in
developing key contacts in China for manufacturing and
distribution. Zhang has extensive knowledge of the Chinese
healthcare market. Her previous position was as General Manager at
Alere China Co. Ltd ("Alere"). During her time at Alere she helped
launch 8 new products and managed 5 product lines. Previously to
this Zhang was at Unipath UK where she helped develop the patented
algorithms currently used by Clearblue's range of fertility and
pregnancy test products.
Zhang is currently managing a hospital evaluation process for
Concepta to support the use of myLotus products for early pregnancy
monitoring. This application is of particular importance in China,
where the use of myLotus is seen as an opportunity to reduce the
overwhelming number of hospital appointments and offer a better way
to manage the early pregnancy period. This will extend the
potential application of myLotus to a considerable number of
pregnancies each year across China.
Erik Henau, CEO says: "We are pleased to have made our first
shipment of test strips to China, and particularly pleased to have
done so with such a quick turnaround time, testament to the quality
of operations at our UK laboratory.
"We are also extremely pleased that Zhang Zhi Gang has taken on
this important role in our Chinese operation, she will be an
important part of the next phase of Concepta's Chinese launch. The
response thus far from Chinese doctors has been very positive and
the additional evaluation to support early pregnancy monitoring is
underway.
"We have been working hard behind the scenes to engage our raw
material suppliers to receive stocks within quoted lead times. In
parallel there is particular attention to the application of our
Quality System and its stringent Quality Assurance standards. We
continue to work closely with our Chinese partners to assemble the
approved products prior to our launch of products into hospitals in
China. We look forward to keeping our shareholders informed on our
progress in China with regular announcements over the coming
months."
Enquiries:
Concepta plc
Adam Reynolds, Chairman / Erik Henau, CEO
Tel: +44 (0) 7785 908158 / +44 (0) 7557 985479
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
Beaufort Securities Limited (Broker)
Jon Belliss
Tel: +44 (0)20 7382 8300
Yellow Jersey PR Limited (Financial PR)
Felicity Winkles / Joe Burgess/ Katie Bairsto
Tel: +44 (0) 7748 843 871
About Concepta Plc:
Concepta plc is a pioneering UK healthcare company that has
developed a proprietary platform and products targeted at the
personalised mobile health market with a primary focus on women's
fertility and specifically unexplained infertility*.
Founded in 2013, Concepta has developed a revolutionary flagship
product 'myLotus' for home self-testing that helps women with
unexplained infertility to conceive.
myLotus is the only consumer product which allows both
quantitative and qualitative measurements of a woman's personal hCG
and LH hormone levels in an easy to use home test to facilitate
higher conception rates and early diagnosis of any fertility
problems. Competitor products currently only allow qualitative
measurement and are based on the 'average woman'.
Concepta has a defined route to market for its new 'myLotus'
product with Regulatory approvals for launch in China in place for
H1 2017 and CE-Marking for UK and Europe to follow later in 2017.
The revenue potential of the Chinese and EU infertility market is
worth c.GBP600m per annum for the company.
*Unexplained infertility refers to women that have been unable
to conceive after 6 months of trying. This highly motivated target
group of consumers won't typically be offered medical intervention
until 12 months of unsuccessfully trying, with IVF not offered
until two years. Research indicates couples start to take positive
action ahead of this time and there is little medical support to
help them do so.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCPGUWARUPMGUW
(END) Dow Jones Newswires
August 23, 2017 07:00 ET (11:00 GMT)
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From Apr 2024 to May 2024
Myhealthchecked (LSE:MHC)
Historical Stock Chart
From May 2023 to May 2024